Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï ÁøÇà¿¡ µû¸¥ Telomerase Activity¹ßÇö ÁõÀÚ Increment of Telomerase Activity with Breast Cancer Progression

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 6È£ p.1032 ~ 1040
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú±ÔÇö ¶ó¼±¿µ/±èżö/À̺´Âù/¹Ú¼¼È£/Á¤Çöö/ÀÌ¿ø¿µ/±èÁÖÇ×/³ëÀç°æ

Abstract

¼­·Ð
¼¼Æ÷°¡ Á¤»óÀû ³ëÈ­ Çö»óÀ» ±Øº¹Çϱâ À§Çؼ­´Â transformation°ú immortalizationÀÌ ¹ß»ý
ÇØ¾ß ÇÑ´Ù. Áï, immortality¸¦ ȹµæÇϱâ À§Çؼ­´Â ¼­·Î ´Ù¸¥ ±âÀü¿¡ ¿ÍÇØ Á¶ÀýµÇ´Â mortality
stage 1 (M1)°ú mortality stage 2 (M2)¸¦ ±Øº¹ÇÒ ¼ö ÀÖ¾î¾ß ÇÑ´Ù. M1 stage´Â Á¤»ó¼¼Æ÷°¡
´õ ÀÌ»ó ºÐ¿­ÇÏÁö ¸øÇÏ°í ¼Ò¸êµÇ´Â ¼¼Æ÷»ç¸ê ½Ã±â·Î ¹ÙÀÌ·¯½º Á¾¾ç´Ü¹é ȤÀº À¯ÀüÀÚ º¯ÀÌ
(p53, Rb À¯ÀüÀÚ)¿¡ ÀÇÇØ ±Øº¹µÈ´Ù. Á¾¾ç À¯ÀüÀÚ¿¡ ÀÇÇØ M1 stage¸¦ ±Øº¹ÇÑ ¼¼Æ÷´Â M2
stage°¡ ¹ß»ýÇÒ ¶§±îÁö ¼¼Æ÷Áõ½Ä´ÉÀÌ À¯ÁöµÇ¾î »ýÁ¸±â°£ÀÌ ¿¬ÀåµÈ´Ù. ±×·¯³ª ´ëºÎºÐÀÇ ¼¼Æ÷
´Â M2 stage¸¦ ±Øº¹ÇÏÁö ¸øÇÏ°í »ç¸êÇϸç, ±ØÈ÷ ÀϺÎÀÇ ¼¼Æ÷¸¸ telomerase°¡ È°¼ºÈ­µÇ¾î
M2 stage¸¦ ±Øº¹ÇÏ°í immortality¸¦ ¾ò°Ô µÈ´Ù.
Àΰ£ÀÇ telomere´Â ¸ðµç ¿°»öü ¸»´ÜºÎÀ§¿¡ TTAGGG 6°³ ÇÙ»êÀÌ ±ÔÄ¢Àû ¹Ýº¹»óÅ·ΠÁ¸
ÀçÇϸç 'end replication problem'¿¡ ÀÇÇØ ¸Å ¼¼Æ÷ ºÐ¿­¸¶´Ù ¼Õ½ÇÀÌ ¹ß»ýÇÑ´Ù. Telomere´Â
¿°»öü ¸»´ÜºÎÀ§¿¡¼­ ¿°»öü°¡ ¼­·Î À¶ÇÕÇϰųª ÀçÁ¶ÇÕÇÏ´Â °ÍÀ» ¹æÁöÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÇÙ¸·
ÁÖÀ§ÀÇ nuclear matrix¿¡ ¿°»öü¸¦ ºÎÂø½ÃÅ´À¸·Î½á DNAse¿¡ ÀÇÇÑ ¿°»öüÀÇ Æı«¸¦ ¹æÁö½Ã
Ų´Ù. µû¶ó¼­ ¹Ýº¹ÀûÀÎ telomereÀÇ ¼Õ½Ç¿¡ ÀÇÇØ ¸»´Ü ºÎÀ§¿¡ telomere°¡ ¾ø´Â ¿°»öü´Â M1
¼¼Æ÷»ç¸ê ±âÀüÀ» È°¼ºÈ­ÇÏ°Ô µÈ´Ù.
±âÁ¸ÀÇ telomerase activity ÃøÁ¤ ¹æ¹ýÀº ¸¹Àº ¼öÀÇ ¼¼Æ÷°¡ ÇÊ¿äÇÒ »Ó´õ·¯ ¹Î°¨µµµµ ³·¾Æ
¼­ ÁÖ·Î º¹¼ö¿¡¼­ äÃëµÈ ¾Ï¼¼Æ÷·Î ½ÃÇàµÇ¾ú´Ù. ±×·¯³ª ¹Î°¨µµ°¡ ¸Å¿ì Áõ°¡µÈ polymerase
chain reactionbased ¹æ¹ý (telomeric repeat amplification protocol: TRAP)ÀÌ °³¹ßµÊ¿¡ µû¶ó
¾ÆÁÖ ÀûÀº ¾çÀÇ Á¶Á÷À¸·Îµµ telomeraseÀÇ È°¼º ÃøÁ¤ÀÌ °¡´ÉÇÏ°Ô µÇ¾ú´Ù. Áõ°¡µÈ teloinerase
È°¼ºÀº ³­¼Ò¾Ï¿¡¼­ ÃÖÃÊ·Î º¸°íµÈ ÀÌ·¡, Ç÷¾×¾Ï, À§¾Ï, Æó¾Ï, °£¾Ï, ´ëÀå¾Ï, ³úÁ¾¾ç, Àü¸³¼±¾Ï,
µÎ°æºÎ¾Ï, À¯¹æ¾Ïµî °ÅÀÇ ¸ðµç¾Ï¿¡¼­ ÁøÂûµÇ¾ú´Ù. ƯÈ÷ Áõ°¡µÈ telomerase È°¼ºÀº À§¾Ï°ú
neuroblastoma¿¡¼­ ȯÀÚÀÇ ºÒ·®ÇÑ ¿¹ÈÄ¿Í °ü·ÃÀÌ ÀÖÀ½À¸·Î º¸°íµÇ¾ú´Ù. ±×·¯³ª ´ëºÎºÐÀÇ Á¤
»ó Á¶Á÷¿¡¼­´Â telomeraseÀÇ È®¼ºÀÌ °ÅÀÇ °üÂûµÇÁö ¾Ê°í ÀÖ´Ù.
º» ¿¬±¸¿¡¼­´Â µ¿ÀÏÀο¡¼­ äÃëµÈ À¯¹æ¾Ï Á¶Á÷°ú Á¤»ó À¯¹æ Á¶Á÷¿¡¼­ telomeraseÀÇ ¹ßÇö
À» Á¶»çÇÑ ´ÙÀ½ ±âÁ¸ÀÇ ¿¹ÈÄ ÀÎÀÚ¿ÍÀÇ »ó°ü¼ºÀ» Á¶»çÇÔÀ¸·Î½á À¯¹æ¾Ï¿¡¼­ telomerase È°¼º
ÀÇ ÀÓ»óÀû ÀÇÀǸ¦ Á¶»çÇÏ¿´´Ù.

Purpose : We studied the telomerase activity in normal and cancer tissues of the
breast and then compared it to the clinical parameters.
Materials and methods : 36 paired normal and cancerous breast tissues were assayed
for telomerase activity by PCR-based TRAP assay(telomeric repeat amplification
protocol). In 17 cancer tissues, flow cytometric analysis for S-phase fraction was done.
Results : None of the normal breast tissue expressed telomerase activity while 23 out
of 26 breast cancer tissue expressed telomerase activity(92%). Clinical parameters such
as T-factor, tumor grade, hormone receptor expression, mitosis, 5-phase fraction did not
correlate with telomerase expression. However, telomerase activity increased with cancer
progression such as; in a state of lymph node metastasis and in an advanced
pathelogical stage.
Conclusion : Telomerase activity was expressed only from cancer tissues. And this
expression increased with cancer progression suggesting a possible therapeutic target in
breast cancer.

Å°¿öµå

Breast cancer; Telomerase;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS